Type 2 Diabetes (T2D) is a growing global health issue, often aggravated by excessive sugar intake. Chronic high-sucrose diets contribute to insulin resistance, oxidative stress, and pancreatic dysfunction, worsening metabolic health. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, like empagliflozin, show potential in improving glycemic control and metabolic parameters, but their effects on pancreatic efficiency in sugar-induced T2D are not well understood. This study aimed to explore the effects of empagliflozin on metabolic and pancreatic protection in a high-sucrose diet-induced T2D model. Male Wistar rats were divided into four groups: normal, normal-treated, diabetic, and diabetic-treated (n = 8 per group). Diabetes was induced with a 35% sucrose solution for 8 weeks, followed by a low-dose streptozotocin (STZ) injection. Treated groups received empagliflozin (15 mg/kg/day) for the duration. Biochemical markers, including fasting blood sugar (FBS), lipid profile, insulin levels, and oxidative stress markers, were measured. Insulin resistance (HOMA-IR) and pancreatic function (HOMA-B) were assessed. Histological analysis of pancreatic tissues was performed. The high-sucrose diet increased FBS, insulin resistance, and oxidative stress, while decreasing pancreatic function and islet diameter. Empagliflozin treatment lowered FBS (p = 0.001), improved insulin sensitivity (p = 0.001), reduced triglycerides (p = 0.001), and LDL (p = 0.05). It also enhanced antioxidant enzymes, reduced lipid peroxidation (MDA, p = 0.001), and preserved pancreatic islet structure (p = 0.001). A high-sucrose diet negatively affects metabolic health and pancreatic function. Empagliflozin mitigates these effects by improving metabolism, reducing oxidative stress, and preserving pancreatic integrity, suggesting its potential as a therapeutic agent in diabetes related to excessive sugar consumption.
| [1] |
Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
|
| [2] |
Zhou B, Rayner AW, Gregg EW, et al. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077-2093.
|
| [3] |
Petrov MS, Basina M. Diagnosis of endocrine disease: diagnosing and classifying diabetes in diseases of the exocrine pancreas. Eur J Endocrinol. 2021;184(4):R151-R163.
|
| [4] |
Son J, Accili D. Reversing pancreatic β-cell dedifferentiation in the treatment of type 2 diabetes. Exp Mol Med. 2023;55(8):1652-1658.
|
| [5] |
Lara-Castor L, O'Hearn M, Cudhea F, et al. Burdens of type 2 diabetes and cardiovascular disease attributable to sugar-sweetened beverages in 184 countries. Nat Med. 2025;31:1-564.
|
| [6] |
Li B, Yan N, Jiang H, et al. Consumption of sugar sweetened beverages, artificially sweetened beverages and fruit juices and risk of type 2 diabetes, hypertension, cardiovascular disease, and mortality: a meta-analysis. Front Nutr. 2023;10:1019534.
|
| [7] |
Arshad S, Rehman T, Saif S, et al. Replacement of refined sugar by natural sweeteners: focus on potential health benefits. Heliyon. 2022;8(9):e10711.
|
| [8] |
Gaesser GA. Refined grain intake and risk of type 2 diabetes. Mayo Clinic Proceedings. Vol 97. Elsevier; 2022:1428-1436.
|
| [9] |
Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: review of the underlying molecular mechanisms. J Cell Physiol. 2019;234(6):8152-8161.
|
| [10] |
Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A. Molecular mechanisms linking oxidative stress and diabetes mellitus. Oxidative Med Cell Longev. 2020;2020(1):8609213.
|
| [11] |
Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review. Life Sci. 2020;240:117090.
|
| [12] |
Yaribeygi H, Maleki M, Reiner Ž, Jamialahmadi T, Sahebkar A. Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. J Clin Med. 2022;11(21):6544.
|
| [13] |
Karasik A, Lanzinger S, Chia-Hui Tan E, et al. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab. 2023;49(2):101418.
|
| [14] |
Kidokoro K, Cherney DZI, Bozovic A, et al. Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation. 2019;140(4):303-315.
|
| [15] |
Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of SGLT2 inhibitors: part 3. Effects on diabetic complications in type 2 diabetic mice. Eur J Pharmacol. 2017;809:163-171.
|
| [16] |
Ye F-Z, Liu WY, Zheng KI, et al. Homeostatic model assessment of insulin resistance closely related to lobular inflammation in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2020;32(1):80-86.
|
| [17] |
Lemaitre RN, Yu C, Hoofnagle A, et al. Circulating sphingolipids, insulin, HOMA-IR, and HOMA-B: the strong heart family study. Diabetes. 2018;67(8):1663-1672.
|
| [18] |
Winterbourn CC, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. J Lab Clin Med. 1975;85(2):337-341.
|
| [19] |
Aebi H. [13] Catalase in vitro. Methods in Enzymology. Elsevier; 1984:121-126.
|
| [20] |
Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27(3):502-522.
|
| [21] |
Satoh M, Fujimoto S, Haruna Y, et al. NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol. 2005;288(6):F1144-F1152.
|
| [22] |
Stanhope KL, Havel PJ. Fructose consumption: considerations for future research on its effects on adipose distribution, lipid metabolism, and insulin sensitivity in humans. J Nutr. 2009;139(6):1236S-1241S.
|
| [23] |
Johnson RJ, Sánchez-Lozada LG, Andrews P, Lanaspa MA. Perspective: a historical and scientific perspective of sugar and its relation with obesity and diabetes. Adv Nutr. 2017;8(3):412-422.
|
| [24] |
Yaribeygi H, Hemmati MA, Nasimi F, et al. Sodium glucose cotransporter-2 inhibitor empagliflozin increases antioxidative capacity and improves renal function in diabetic rats. J Clin Med. 2023;12(11):3815.
|
| [25] |
Yaribeygi H, Hemmati MA, Nasimi F, Pakdel R, Jamialahmadi T, Sahebkar A. Empagliflozin alleviates diabetes-induced cognitive impairments by lowering nicotinamide adenine dinucleotide phosphate oxidase-4 expression and potentiating the antioxidant defense system in brain tissue of diabetic rats. Behav Brain Res. 2024;460:114830.
|
| [26] |
Wanner C, Nangaku M, Kraus BJ, et al. How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial. Nephrol Dial Transplant. 2024;39(9):1504-1513.
|
| [27] |
Ferreira JP, Inzucchi SE, Mattheus M, et al. Empagliflozin and uric acid metabolism in diabetes: a post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022;24(1):135-141.
|
| [28] |
Anyanwu OA, Folta SC, Zhang FF, et al. A cross-sectional assessment of dietary patterns and their relationship to hypertension and obesity in Indonesia. Curr Dev Nutr. 2022;6(6):nzac091.
|
| [29] |
Lourido F, Quenti D, Salgado-Canales D, Tobar N. Domeless receptor loss in fat body tissue reverts insulin resistance induced by a high-sugar diet in Drosophila melanogaster. Sci Rep. 2021;11(1):3263.
|
| [30] |
Epstein LH, Biondolillo MJ, Rizwan A, et al. Insulin resistance and glycated hemoglobin in obesity are associated with preference for sugar-sweetened yogurt: a pilot study. Psychosom Med. 2023;85(3):289-293.
|
| [31] |
Balakumar M, Raji L, Prabhu D, et al. High-fructose diet is as detrimental as high-fat diet in the induction of insulin resistance and diabetes mediated by hepatic/pancreatic endoplasmic reticulum (ER) stress. Mol Cell Biochem. 2016;423:93-104.
|
| [32] |
Gugliucci A. Sugar and dyslipidemia: a double-hit, perfect storm. J Clin Med. 2023;12(17):5660.
|
| [33] |
Song Q, Kikumoto A, Sun S, Mochizuki S, Oda H. High fat intake aggravates hyperlipidemia and suppresses fatty liver symptoms induced by a high-sucrose diet in rats. Food Funct. 2024;15(20):10516-10526.
|
| [34] |
Verma S, Kosmopoulos A, Bhatt DL, et al. Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: a post hoc subgroup analysis of EMPA-REG outcome: analysis of EMPA-REG OUTCOME using REDUCE-IT criteria. Am J Prevent Cardiol. 2023;15:100510.
|
| [35] |
Gaborit B, Ancel P, Abdullah AE, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20:1-14.
|
| [36] |
Arias-Chávez DJ, Mailloux-Salinas P, Altamirano J, Huang F, Gómez-Viquez NL, Bravo G. Consumption of combined fructose and sucrose diet exacerbates oxidative stress, hypertrophy and CaMKIIδ oxidation in hearts from rats with metabolic syndrome. Mol Cell Biochem. 2022;477(4):1309-1320.
|
| [37] |
Zhao Z-z, Xin L-l, Xia J-h, Yang S-l, Chen Y-x, Li K. Long-term high-fat high-sucrose diet promotes enlarged islets and β-cell damage by oxidative stress in bama minipigs. Pancreas. 2015;44(6):888-895.
|
| [38] |
Eguchi N, Vaziri ND, Dafoe DC, Ichii H. The role of oxidative stress in pancreatic β cell dysfunction in diabetes. Int J Mol Sci. 2021;22(4):1509.
|
| [39] |
Uthman L, Li X, Baartscheer A, et al. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na+] c/ROS-pathway in human endothelial cells. Biomed Pharmacother. 2022;146:112515.
|
| [40] |
Asahara S-i, Ogawa W. SGLT2 Inhibitors and Protection Against Pancreatic Beta Cell Failure. Springer; 2019:1-2.
|
| [41] |
Zidan D, Azlan A, Abas F, et al. Effect of less refined sugar (LRS) vs. refined sugar (RS) on postprandial glycaemic responses, glycaemic profile, and lipid profile, in normal and type 1 diabetic rats: a preliminary study. Int Food Res J. 2024;31(5):1336-1350.
|
RIGHTS & PERMISSIONS
2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.
PDF
